Table 3 Adverse events in 64 patients with sarcoma treated with apatinib
From: Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
Adverse eventsa | Grade 1 | Grade 2 | Grade 3 | Total |
|---|---|---|---|---|
Hypertension | 11 | 8 | 5 | 24(37.50%) |
Hand-foot syndrome | 9 | 10 | 3 | 22(34.38%) |
Proteinuria | 11 | 6 | 2 | 19(29.69%) |
Anorexia | 10 | 4 | 14(21.88%) | |
Fatigue | 7 | 2 | 1 | 8(12.50%) |
Pain | 4 | 2 | 1 | 7(10.94%) |
Diarrhea | 6 | 1 | 7(10.94%) | |
Mucositis | 3 | 2 | 5(7.81%) | |
Skin pigmentation | 5 | 5(7.81%) | ||
Rash | 5 | 5(7.81%) | ||
Transaminase increased | 3 | 1 | 4(6.25%) | |
Anemia | 4 | 4(6.25%) | ||
Hiccough | 4 | 4(6.25%) | ||
Bilirubin increased | 2 | 1 | 3(4.69%) | |
Dyspnea | 2 | 1 | 3(4.69%) | |
Periodontal disease | 3 | 3(4.69%) | ||
Aerothorax | 1 | 1 | 2(3.13%) | |
Hematuria | 2 | 2(3.13%) | ||
Dizziness | 2 | 2(3.13%) | ||
Palpitation | 2 | 2(3.13%) | ||
Hypogeusia | 1 | 1(1.56%) | ||
Fever | 1 | 1(1.56%) |
